TABLE 3
FROM:
Phase I Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy Combined with IMRT for Prostate Cancer
Svend O Freytag, Benjamin Movsas, Ibrahim Aref, Hans Stricker, James Peabody, Jan Pegg, Yingshu Zhang, Kenneth N Barton, Stephen L Brown, Mei Lu, Adnan Savera and Jae Ho Kim
BACK TO ARTICLETable 3. Comparison of adverse events in Office of Biotechnology Activities protocols 0307-590 and 0104-464
| Likely attribution ofadverse event | Protocol 0307-590 (Ad5-yCD/mutTKSR39 rep-ADP) | Protocol 0104-464 (Ad5-CD/TKrep) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Grade (% of patients) | Grade (% of patients) | |||||||||
| 1 | 2 | 3 | 4 | Total | 1 | 2 | 3 | 4 | Total | |
| Adenoviral therapy | ||||||||||
| SGOT/SGPT | 44 | 44 | 33 | 7 | 40 | |||||
| Prodrug therapy | ||||||||||
| Anemia | 33 | 11 | 44 | 67 | 67 | |||||
| Leukopenia | 33 | 11 | 44 | 53 | 13 | 67 | ||||
| Lymphopenia | 11 | 56 | 22 | 89 | 80 | 13 | 93 | |||
| Neutropenia | 22 | 22 | 20 | 20 | ||||||
| Thrombocytopenia | 11 | 11 | 27 | 27 | ||||||
| Radiation therapy | ||||||||||
| RTOG gastrointestinal | 33 | 33 | 67 | 27 | 27 | 54 | ||||
| RTOG genitourinary | 22 | 44 | 67 | 67 | 27 | 7 | 100 | |||
| Fatigue | 11 | 11 | 40 | 7 | 47 | |||||
| Unknown | ||||||||||
| Hyperglycemia | 11 | 11 | 22 | 7 | 33 | 7 | 47 | |||
Abbreviations: RTOG, Radiation Therapy Oncology Group; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.
